AI assistant
Iterum Therapeutics plc — Director's Dealing 2018
May 25, 2018
34796_dirs_2018-05-24_fefa5c26-57d4-4737-adb5-e788d0cec37c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-05-24
Reporting Person: Chin Mark (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series B-1 Preferred Shares | $ | Ordinary Shares (445576) | Indirect | ||
| Series B-2 Preferred Shares | $ | Ordinary Shares (248721) | Indirect |
Footnotes
F1: The Series B-1 Preferred Shares are convertible into Ordinary Shares of the Issuer at the option of the holder. The Series B-1 Preferred Shares will automatically convert into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
F2: Not applicable.
F3: The Reporting Person is an Investment Director for Arix Bioscience Holdings Ltd.
F4: The Series B-2 Preferred Shares are convertible into Ordinary Shares of the Issuer at the option of the holder. The Series B-2 Preferred Shares will automatically convert into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.